Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

467P - Monocyte to red blood cells ratio (MRR): an innovative haematologic prognostic parameter in FOLFIRI-aflibercept treated patients: A subgroup analysis from the DISTINCTIVE trial

Date

16 Sep 2021

Session

ePoster Display

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Eleonora Lai

Citation

Annals of Oncology (2021) 32 (suppl_5): S530-S582. 10.1016/annonc/annonc698

Authors

E. Lai1, S. Murgioni2, P. Ziranu1, D. Basile3, S. Cherri4, C. Madeddu1, F. Bergamo2, G. Piacentini5, V. Smiroldo6, M. Squadroni7, M.C. De Grandis8, L. Mascia9, G. Rosati10, M.G. Zampino11, A. Spallanzani12, V. Conca13, M.A. Palladino14, V. Flaminio15, S. Di Bella16, M. Scartozzi1

Author affiliations

  • 1 Medical Oncology Unit, University Hospital and University of Cagliari, 09042 - Monserrato/IT
  • 2 Medical Oncology Unit 1, Department Of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua/IT
  • 3 Department Of Oncology, San Bortolo General Hospital, Azienda ULSS8 Berica, Vicenza/IT
  • 4 Medical Oncology Unit, Fondazione Poliambulanza, Brescia/IT
  • 5 Oncologia Medica, Presidio Ospedaliero SS Antonio e Biagio e Cesare Arrigo, Alessandria/IT
  • 6 Medical Oncology And Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan/IT
  • 7 Oncologia Medica, Humanitas Gavazzeni Bergamo, Bergamo/IT
  • 8 1) Department Of Surgery, Oncology And Gastroenterology, 2) Medical Oncology Unit 1, Department Of Oncology, University of Padua; Veneto Institute of Oncology IOV - IRCCS, Padua/IT
  • 9 Medical Oncology Unit, Arnas G. Brotzu, ARNAS G. Brotzu, Ospedale Businco, Cagliari/IT
  • 10 U.o. Oncologia Medica, Ospedale S. Carlo, Potenza/IT
  • 11 Divisione Di Oncologia Medica Gastrointestinale E Tumori Neuroendocrini, Istituto Europeo di Oncologia-IRCCS Milan, Italy, Milan/IT
  • 12 Department Of Oncology And Haematology, Division Of Oncology, University Hospital of Modena, Modena/IT
  • 13 Unit Of Medical Oncology 2 Department Of Translational Research And New Technology In Medicine And Surgery, Azienda Ospedaliero-Universitaria Pisana; University of Pisa, Pisa/IT
  • 14 Oncology & Hematology Department, Oncology Unit, Piacenza General Hospital, Piacenza/IT
  • 15 Medical Oncology Unit, Internal Medicine Department "tor Vergata", "Tor Vergata" University Hospital, Rome/IT
  • 16 Alta Specialità Oncologia Medica, Uo Oncologia Medica, Asst Rhodense - Presidio Di Garbagnate, Italy, ASST Rhodense - Presidio di Garbagnate, Italy, Garbagnate Milanese/IT
More

Abstract 467P

Background

Recently, laboratory parameters have been explored as potential prognostic biomarkers in several tumour types. Here we present our findings in the population enrolled in the interim analysis of the DISTINCTIVE trial (NCT04252456), a prospectively stratified, biologically enriched phase II study of second-line FOLFIRI-aflibercept in RAS wild type (wt) metastatic colorectal cancer (mCRC) patients (pts) progressing after first-line anti-epidermal growth factor receptor (EGFR) drugs.

Methods

RAS wt mCRC pts resistant to first-line oxaliplatin-based chemotherapy + anti-EGFR are administered second-line FOLFIRI-aflibercept. Primary endpoint is overall survival (OS) according to VEGFR2 levels, whereas secondary endpoints are OS, progression free survival (PFS), response rate, safety and angiogenic factors levels. Clinical and laboratory data are collected to evaluate their correlation with outcome. Statistical analysis is performed with MedCalc (survival distribution: Kaplan-Meier; survival comparison: log-rank test; cut off: ROC curves).

Results

Of 73 pts enrolled from 04/2018 to 06/2020, 44 were eligible for interim analysis. Among the laboratory values assessed, monocytes (M), red blood cells (RBC) and M/RBC ratio (MRR) were of particular interest. Better OS was related to lower (≤0.7x103/μl) M (14.2 months [95%CI:10.4-14.2] vs 6.8 months [95%CI:0.5-6.8], HR 0.003, p=0.0002) and higher (>3.81x106/μl) RBC (14.2 months [95%CI:10.4-14.2] vs 6.8 months [95%CI:0.5-9.1], HR 0.005, p< 0.0001). Longer PFS was correlated with lower M (8.5 months [95% CI:5.3-24.2] vs 4.2 months [95%CI:3.9-5.8], HR 0.18, p=0.0266) and higher RBC (8.5 months [95%CI:5.7-24.2) vs 2.5 months [95%CI:2.1-4.2], HR 0.04, p=0.0007). Lower MRR (≤1528) was related to improved OS (14.2 months [95%CI:10.4-14.2] vs 6.8 months [95%CI:0.5-6.8], HR 0.004, p=0.0003) and PFS (8.5 months [95%CI:5.3-24.2] vs 4.2 months [95%CI:3.9-5.8], HR 0.24, p=0.0492).

Conclusions

Our analysis confirmed the prognostic role of some haematologic parameters and an innovative and easy-to assess ratio in RAS wt mCRC pts receiving FOLFIRI-aflibercept.

Clinical trial identification

NCT04252456.

Editorial acknowledgement

Legal entity responsible for the study

GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente).

Funding

GISCAD; this study was partially supported by Sanofi Genzyme.

Disclosure

M. Scartozzi: Financial Interests, Personal, Advisory Board: Amgen; Sanofi; MSD; Eisai; Merck; Bayer; Financial Interests, Personal, Speaker’s Bureau: Amgen; Sanofi; MSD; Eisai; Merck; Bayer; Financial Interests, Personal, Other, Consultant: Amgen; Sanofi; MSD; Eisai; Merck; Bayer; All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.